 |
|
Pharmacoeconomic Considerations in Pharmaceutical Company Promotions-Reply
Timothy J. Ives, PharmD, MPH;
Adam O. Goldstein, MD
University of North Carolina at Chapel Hill
Arch Fam Med. 1995;4(8):675.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In reply
In response to Rosenberg's letter, we commend Bayer (formerly Miles Inc) for lowering the price of their extended-release nifedipine product and challenge them to continue to keep their cost lower than that of other brands of nifedipine with a once-daily formulation. As noted by Rosenberg, we look forward to "significant cost reduction."
We recognize and commend Rosenberg's efforts to explain the specific issues regarding the cost differential between the two pharmaceutical companies who distribute extended-release nifedipine. Such an explanation, unfortunately, was not clear to us in looking at their six pages of color advertisement in the ARCHIVES and other journals.
In our original comparison (and we assume, the comparison used by most practicing clinicians), the issue is not to compare Adalat CC with only Procardia XL, but with other potential pharmacotherapies in the patient population who may use this type of agent. If that comparison is performed, the differences are
. . . [Full Text PDF of this Article]
|
